Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Components

v3.20.1
Balance Sheet Components
 3 Months Ended
Mar. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Balance Sheet Components

NOTE 6 — BALANCE SHEET COMPONENTS

Accrued liabilities consisted of the following (in thousands):

 

 

 

March 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Accrued liabilities:

 

 

 

 

 

 

 

 

General and administrative

 

$

2,034

 

 

$

4,521

 

Clinical trial related costs

 

 

1,696

 

 

 

1,383

 

Non-clinical research and manufacturing operations

 

 

6,119

 

 

 

5,774

 

Payroll related

 

 

1,659

 

 

 

2,849

 

Other accrued expenses

 

 

23

 

 

 

17

 

Total Accrued liabilities

 

$

11,531

 

 

$

14,544